A multi-dose pharmacokinetic study of dalteparin in haemodialysis patients

Thrombosis and Haemostasis

Volumn 96, Issue 6, 2006, Pages 750-755

  Perry, Stephanie L ^a   O'Shea, Susan I ^b,c   Byrne, Stephen ^c   Szczech, Lynda A ^a   Ortel, Thomas L ^a  

^a DUKE UNIVERSITY HEALTH SYSTEM   (United States)

^b University College Cork and INFANT Centre   (Ireland)

^c UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Dalteparin; Hemodialysis; Low molecular weight heparin; Pharmacokinetics

Indexed keywords

BLOOD CLOTTING FACTOR 10A; DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BLOOD SAMPLING; BLOOD VESSEL GRAFT; BODY WEIGHT; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; MALE; PILOT STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOSIS; VASCULAR ACCESS;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; AREA UNDER CURVE; BODY WEIGHT; DALTEPARIN; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FACTOR XA; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PILOT PROJECTS; RENAL DIALYSIS;

EID: 33845373392     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-01-0006     Document Type: Article

References (24)

1. Farooq V, Hegarty J, Chandrasekar T, et al. Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease. Am J Kidney Dis 2004; 43: 531-7.
2. Thorevska, N, Amoateng-Adjepong Y, Sabahi R, et al. Anticoagulation in hospitalized patients with renal insufficiency: A comparision of bleeding rates with unfractionated heparin vs enoxaparin. Chest 2004; 125: 856-63.
3. Collet J, Montalescot G, Choussat R, et al. Enoxaparin in unstable angina patients with renal failure. Int J Cardiol 2001; 80: 81-2.
4. Becker RC, Spencer FA, Gibson M, et al. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J 2002; 143: 753-9.
5. Spinler SA, Inverso SM, Cohen M, et al. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obsese and patients with severe renal impairment: Analysis from the ESSENCE and TIMI 11B studies. Am Heart J 2003, 146: 33-41.
6. Nagge J, Crowther M, Hirsh J. Is impaired renal function a contraindiction to the use of low-molecular-weight heparin? Arch Intern Med 2002; 162: 2605-9.
7. Lim W, Cook DJ, Crowther MA. Safety and efficacy of low molecular weight heparin for hemodialysis in patients with end-stage renal failure: A meta-analysis of randomized trials. J Am See Nephrol 2004; 15: 3192-206.
8. Borm JJJ, Krediet R, Sturk A, et al. Heparin versus low molecular weight heparin K 2165 in chronic hemodialysis patients: A randomized cross-over study. Haemostasis 1986; 16: 59 68.
9. Schrader J, Stibbe W, Armstrong VW, et al. Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration. Kidney Int 1988; 33: 890-6.
10. Anastassiades E, Lane DA, Ireland H, et al. A low molecular weight heparin ("fragmin") for routine hemodialysis: a crossover trial comparing three dose regimens with a standard regimen of commercial unfractionated heparin. Clin Nephrol 1989; 32: 290-6.
11. Anastassiades E, Ireland H, Flynn A, et al. A low-molecular-weight heparin (Kabi 2165, 'Fragmin') in repeated use for haemodialysis: Prevention of clotting and prolongation of the venous compression time in comparison with commercial unfractionated heparin. Nephrol Dial Transplant 1990; 5: 135-40.
12. Sagedal S, Hartmann A, Sundstrom K, et al. A single dose of dalteparin effectively prevents clotting during haemodialysis. Nephrol Dial Transplant 1999; 14: 1943-7.
13. Polkinghorne KR, McMahon LP, Becker GJ. Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. Am J Kidney Dis 2002; 40: 990-5.
14. O'Shea SI, Lawson JH, Reddan D, et al. Hyper-coagulable states and antithrombotic strategies in recurrent vascular access site thrombosis. J Vasc Surg 2003; 38: 1-8.
15. Lim W, Dentali F, Eikelboom J, et al. Meta-analysis: Low molecular weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006 144: 673-84.
16. Lim W, Douketis J, Wang L, et al. Anti-Xa levels and renal function: Analysis of the first 32 patients in the Tinzaparin in Renal Insufficiency for Venous Thromboembolism Study. Blood 2005; 106: Abstract#906.
17. Mahe I, dit Solier CB, Aghassarian M. et al. A comparative pharmacodynamic study of anti-Xa activitiy to evaluate the accumulation effect of tinzaparin and enoxaparin given prophylactic dose over 8 days in medical elderly patients with impaired renal function. Blood 2005; 106: Abstract#4152.
18. Rabbat CG, Cook DJ, Crowther MA, et al. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency. J Crit Care 2005; 20: 357-63.
19. Cook DJ, Rocker G, Meade M. et al.; for the PROTECT Investigators and the Canandian Critical Care Trials Group. Prophylaxis of Thromboembolism in Critical Care (PROTECT) Trial: a pilot study. J Crit Care 2005 20: 364-72.
20. Reeves JH, Cumming AR, Gallagher L, et al. A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Crit Care Med 1999; 27: 2224-8.
21. Eriksson BE, Soderberg K, Widlund L, et al. A comparative study of three low-molecular-weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers. Thromb Haemost 1995; 73: 398-401.
22. Collignon F, Frydman A, Caplain Het al. Comparison of the pharmacokinetic profiles of three low molecular mass heparins - dalteparin, enoxaparm and nadroparin - administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 1995; 73: 630-40.
23. Amin NB, Padhi ID, Touchette MA, et al. Characterization of gentamicin pharmacokinctics in patients hemodialyzed with high-flux ploysulfone membranes. Am J Kidney Dis 1999; 34: 222-7.
24. Chaignon M, Chen WT, Tarazi RC, et al. Effect of hemodialysis on blood volume distribution and cardiac output. Hypertension 1981; 3: 327-32.